Insights
More Articles
- Venetoclax gains MHRA nod to treat newly diagnosed AML
- EMA: Capillary leak syndrome an AZ vaccine side effect
- Earmuffs to measure blood alcohol level
- Pfizer/BioNTech vaccine approved by Vietnam officials
- 3 FDA panel members resign after Alzheimer's drug approval
Venetoclax gains MHRA nod to treat newly diagnosed AML
AbbVie and Roche's Venclyxto, or venetoclax, combined with a hypomethylating agent, has been approved by the UK's Medicines and Healthcare products Regulatory Agency to treat patients newly diagnosed with acute myeloid leukemia who are not eligible for intensive chemotherapy. PharmaTimes online (UK) (6/11)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!